Obseva SA (NASDAQ:OBSV) was the recipient of a large increase in short interest in the month of July. As of July 31st, there was short interest totalling 247,200 shares, an increase of 31.8% from the June 30th total of 187,600 shares. Based on an average daily trading volume, of 48,400 shares, the days-to-cover ratio is presently 5.1 days. Approximately 1.2% of the company’s shares are sold short.
Several large investors have recently bought and sold shares of OBSV. Capital Investment Advisory Services LLC acquired a new position in shares of Obseva in the second quarter worth $40,000. Geode Capital Management LLC purchased a new stake in shares of Obseva during the 4th quarter worth $159,000. Jane Street Group LLC purchased a new stake in shares of Obseva during the 4th quarter worth $218,000. Wedbush Securities Inc. lifted its position in shares of Obseva by 86.1% during the 1st quarter. Wedbush Securities Inc. now owns 38,790 shares of the company’s stock worth $496,000 after purchasing an additional 17,950 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Obseva by 274.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 70,573 shares of the company’s stock worth $893,000 after purchasing an additional 51,733 shares during the last quarter. Institutional investors and hedge funds own 63.55% of the company’s stock.
Several research firms recently weighed in on OBSV. Royal Bank of Canada reiterated a “buy” rating on shares of Obseva in a report on Sunday. Wedbush reiterated an “outperform” rating and issued a $38.00 target price on shares of Obseva in a report on Thursday, July 18th. Credit Suisse Group dropped their target price on shares of Obseva from $24.00 to $16.00 and set an “outperform” rating for the company in a report on Monday, July 29th. HC Wainwright set a $44.00 target price on shares of Obseva and gave the company a “buy” rating in a report on Wednesday, June 5th. Finally, ValuEngine upgraded shares of Obseva from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $27.50.
Shares of NASDAQ:OBSV traded up $0.02 during trading on Wednesday, hitting $9.00. The company’s stock had a trading volume of 597 shares, compared to its average volume of 48,128. The firm’s 50 day simple moving average is $10.06. The stock has a market cap of $417.05 million, a P/E ratio of -4.62 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.67 and a quick ratio of 3.67. Obseva has a fifty-two week low of $8.22 and a fifty-two week high of $19.40.
Obseva (NASDAQ:OBSV) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.22). On average, equities analysts predict that Obseva will post -2.89 earnings per share for the current year.
Obseva Company Profile
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.
Further Reading: How to invest in a bear market
Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.